<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601835</url>
  </required_header>
  <id_info>
    <org_study_id>TDC01</org_study_id>
    <nct_id>NCT00601835</nct_id>
  </id_info>
  <brief_title>Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td</brief_title>
  <official_title>Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the seroprotection rates and booster responses to Canadian-manufactured Tetanus
      and Diphtheria Toxoids Adsorbed vaccine to the seroprotection rates and booster responses to
      the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to
      subjects ≥ 60 years of age.

      To compare the post-vaccination geometric mean titers of antibody (GMTs) to Canadian
      manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the post-vaccination GMTs to
      the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to
      subjects ≥ 60 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, partially open-label, partially randomized double blind trial for
      immunogenicity and safety in the United States. Participants will be enrolled to one of three
      treatment groups:

        -  Subjects ages 11-59 years will receive Canadian manufactured Td vaccine on Day 0

        -  Subjects 60 years or older will be randomized to receive either US manufactured Td on
           Day 0, or,

        -  Subjects 60 years or older randomized to receive Canadian manufactured Td on Day 0

      The trial is designed to assess the safety of Canadian Manufactured Tetanus and Diphtheria
      Toxoids Adsorbed vaccine in all trial participants 11 to 59 years of age and to describe the
      immune responses in subsets of adolescents (11-14, and 15-18 years of age) and in a subset of
      adults 19-59 years of age. The trial will also compare the immune responses and safety in
      subjects ≥ 60 years of age receiving Canadian Manufactured Tetanus and Diphtheria Toxoids
      Adsorbed vaccine to an equal number of subjects ≥ 60 years of age receiving US Manufactured
      Tetanus and Diphtheria Toxoids Adsorbed vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.</measure>
    <time_frame>28 Days post-vaccination</time_frame>
    <description>Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</measure>
    <time_frame>28 Days post-vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</measure>
    <time_frame>0-14 days post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3651</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Canadian Td Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Canadian manufactured Td vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>United States Td Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received US manufactured Td vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular, single dose</description>
    <arm_group_label>Canadian Td Vaccine Group</arm_group_label>
    <other_name>TENIVAC™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular, Single dose</description>
    <arm_group_label>United States Td Vaccine Group</arm_group_label>
    <other_name>DECAVAC®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is healthy as per medical history reported by subject.

          -  Participant is at least 11 years of age at the time of vaccination.

          -  Participant has a signed Institutional Review Board (IRB)-approved informed
             assent/consent form. For subjects 11 to 17 years of age, a written informed consent
             must be obtained from parent(s) or legal guardian(s) and a written informed assent
             must be obtained from the subject

          -  Participant provides history or documentation of primary or booster immunization with
             Diphtheria and Tetanus.

          -  Female participants of childbearing potential must have a negative urine pregnancy
             test at the time of enrollment.

        Exclusion Criteria:

          -  Serious and uncontrolled chronic disease (i.e., cardiac, pulmonary, renal, neurologic,
             metabolic, rheumatologic, etc.).

          -  Known or suspected impairment of immunologic function.

          -  Acute medical illness with or without fever within the last 72 hours or an oral
             temperature ≥ 100.4°F (≥ 38°C) at the time of enrollment.

          -  Administration of immune globulin or other blood products within the last three
             months; administration of corticosteroids (injected or oral) or other immunomodulatory
             therapy within six weeks of the study vaccine. However, individuals on a tapering dose
             schedule of oral steroids may be included in the trial, as long as steroids were
             discontinued more than two weeks prior to enrollment.

          -  Received any vaccine, other than influenza vaccine, in the 28-day period prior to
             enrollment or scheduled to receive any vaccination, other than influenza prior to
             Visit 2 blood draw. For influenza vaccine only, exclude if received in the 14 day
             period prior to enrollment or scheduled to receive in the 14 day period after Visit 1.

          -  Suspected or known hypersensitivity to Td components, thimerosal (for subjects &gt; 60
             years of age) or latex rubber.

          -  Unable to attend scheduled visits or unable to comply with the study procedures.

          -  Enrolled in another clinical trial.

          -  Any condition that would pose a health risk to the participant or interfere with the
             evaluation of the vaccine in the opinion of the investigator.

          -  A positive urine pregnancy test at the time of enrollment for all females of
             childbearing potential.

          -  Female of childbearing potential who does not agree either to remain abstinent or to
             use effective birth control during the period of the trial.

          -  Breast feeding during the period of the trial.

          -  A history of Guillain- Barré syndrome within 6 weeks after a previous dose of a
             tetanus toxoid-containing vaccine.

          -  Receipt of a tetanus or diphtheria vaccination within the 5 years prior to enrollment.

          -  A previous history of diphtheria disease within the last 25 years or tetanus disease

          -  History of Arthus-type hypersensitivity reaction or a temperature &gt;103° F following a
             prior dose of tetanus toxoid, unless 10 years have elapsed since the previous dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>http://www.sanofipasteur.com</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>November 16, 2009</results_first_submitted>
  <results_first_submitted_qc>January 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2011</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in the study from 06 May 2004 through 13 December 2004, in 2 medical sites (4 investigators) in the US.</recruitment_details>
      <pre_assignment_details>A total of 3,651 participants that met the inclusion and exclusion criteria were enrolled in the study. One participant declined vaccination.
The immunogenicity subsets consist of all participants ≥ 60 years of age; the safety subsets consist of all participants ≥ 60 years of age and one third of participants 11 to 59 years of age.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Canadian Td Vaccine Group</title>
          <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
        </group>
        <group group_id="P2">
          <title>United States Td Vaccine Group</title>
          <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2950"/>
                <participants group_id="P2" count="700"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2890"/>
                <participants group_id="P2" count="686"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocate</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Canadian Td Vaccine Group</title>
          <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
        </group>
        <group group_id="B2">
          <title>United States Td Vaccine Group</title>
          <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2950"/>
            <count group_id="B2" value="700"/>
            <count group_id="B3" value="3650"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1501"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1000"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="1257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="443"/>
                    <measurement group_id="B3" value="892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="23.49"/>
                    <measurement group_id="B2" value="69.3" spread="7.89"/>
                    <measurement group_id="B3" value="40.5" spread="25.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1629"/>
                    <measurement group_id="B2" value="403"/>
                    <measurement group_id="B3" value="2032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1321"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="1618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2950"/>
                    <measurement group_id="B2" value="700"/>
                    <measurement group_id="B3" value="3650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.</title>
        <description>Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.</description>
        <time_frame>28 Days post-vaccination</time_frame>
        <population>Seroprotection and Booster Responses to Tetanus and Diphtheria were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Canadian Td Vaccine Group</title>
            <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
          </group>
          <group group_id="O2">
            <title>United States Td Vaccine Group</title>
            <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.</title>
          <description>Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.</description>
          <population>Seroprotection and Booster Responses to Tetanus and Diphtheria were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetanus Post-vaccination Seroprotection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria Post-vaccination Seroprotection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus Booster Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria Booster Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</title>
        <time_frame>28 Days post-vaccination</time_frame>
        <population>Geometric mean titers were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population</population>
        <group_list>
          <group group_id="O1">
            <title>Canadian Td Vaccine Group</title>
            <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
          </group>
          <group group_id="O2">
            <title>United States Td Vaccine Group</title>
            <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</title>
          <population>Geometric mean titers were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetanus post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" lower_limit="6.01" upper_limit="7.77"/>
                    <measurement group_id="O2" value="7.35" lower_limit="6.54" upper_limit="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.459" lower_limit="0.371" upper_limit="0.567"/>
                    <measurement group_id="O2" value="0.409" lower_limit="0.332" upper_limit="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</title>
        <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.</description>
        <time_frame>0-14 days post-vaccination</time_frame>
        <population>Solicited safety parameters were in all enrolled and vaccinated participants ≥ 60 years of age and one third of participants 11 to 59 years of age. A subset of the intend-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Canadian Td Vaccine Group</title>
            <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
          </group>
          <group group_id="O2">
            <title>United States Td Vaccine Group</title>
            <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.</title>
          <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.</description>
          <population>Solicited safety parameters were in all enrolled and vaccinated participants ≥ 60 years of age and one third of participants 11 to 59 years of age. A subset of the intend-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1450"/>
                <count group_id="O2" value="700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="832"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site pain (require medical care)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site redness (≥ 50 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site swelling (≥ 50 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Chills (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Diarrhea (≥ 5 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (≥ 39.0 °C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle weakness (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Nausea (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain in joints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain in joints (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (≥ 3 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 6 months post-vaccination in all participants enrolled in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Canadian Td Vaccine Group</title>
          <description>Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)</description>
        </group>
        <group group_id="E2">
          <title>United States Td Vaccine Group</title>
          <description>Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2950"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Moebius II syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Hepatic trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Colon Cacer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Paraganglion neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Post-traumatic headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease exacerbated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="832" subjects_at_risk="2950"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="700"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="152" subjects_affected="152" subjects_at_risk="1434"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="693"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="106" subjects_affected="106" subjects_at_risk="1434"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="832" subjects_affected="832" subjects_at_risk="1434"/>
                <counts group_id="E2" events="209" subjects_affected="209" subjects_at_risk="693"/>
              </event>
              <event>
                <sub_title>Injection site redness</sub_title>
                <counts group_id="E1" events="299" subjects_affected="299" subjects_at_risk="1434"/>
                <counts group_id="E2" events="132" subjects_affected="132" subjects_at_risk="693"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="205" subjects_affected="205" subjects_at_risk="1434"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="693"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="80" subjects_affected="80" subjects_at_risk="1434"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="693"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="95" subjects_at_risk="1427"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="687"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="226" subjects_affected="226" subjects_at_risk="1433"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="692"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="267" subjects_affected="267" subjects_at_risk="1434"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="692"/>
              </event>
              <event>
                <sub_title>Pains in joints</sub_title>
                <counts group_id="E1" events="201" subjects_affected="201" subjects_at_risk="1434"/>
                <counts group_id="E2" events="74" subjects_affected="74" subjects_at_risk="693"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="380" subjects_affected="380" subjects_at_risk="1434"/>
                <counts group_id="E2" events="122" subjects_affected="122" subjects_at_risk="693"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

